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Diagnosis and Treatment 
Options for MS 
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History of MS 
■ Thought to be immune mediated 
– Virally triggered in genetically susceptible host 
 
■ Treatments 
– Acute attacks: ACTH in 1970s–1980s 
– Disease modification in 1990s 
– Symptomatic management 
 
■ Diagnostic tests 
– MRI in 1980s 
– New MRI techniques 
What We Know Now… 
■ Most common neurological disease of young adults 
 
■ Chronic disease of the CNS 
– Inflammation, demyelination, axonal degeneration 
 
■ Approximately 350,000 cases in US 
 
■ 2/3 of MS patients are women 
 
■ Associated with Northern European ancestry 
 
■ Age of onset: 15–55 
– Usually diagnosed in 20s–30s 
Statistics 
■ Worldwide distribution 
– High prevalence 30+/100,000 
• Northern US and Canada 
• Most of Europe 
• Southern Australia  
• New Zealand 
• Northeast Russia 
Pathology 
■ White matter lesions in CNS 
– Surrounded by plasma cells, 
immunoglobulins, macrophages, and 
lymphocytes 
 
■ Grey Matter 
– Cortex, Basal Ganglia 
 
■ Inflammation 
– Myelin injury and destruction 
– Axonal injury and destruction 
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Reprinted with permission from Trapp BD et al. N Engl J Med. 1998;338:278-285. Copyright 
 
1998 Massachusetts Medical Society. All rights reserved. 
Demyelination and Axonal 
Transection 
Disease Course 
■ 85%–90% of patients present with a RR pattern of 
neurological symptoms  
 
■ 10%–15% never have relapses (PP) 
 
■ Historically - After approximately 10 years, nearly 50% 
of RR patients will show a progressive pattern to their 
disease   
– This percentage grows with time 
– Now believed longer than 10 years due to earlier 
treatment 









































Disease Courses in MS 
Weinshenker BG et al. Brain. 1989;112:133-146. 
RRMS 
PPMS 
Disease Type at Diagnosis Disease Type at 11–15 Years  
After Diagnosis (Among Those 







Natural History Over Time 




■ Sensory disturbances 
■ Visual disturbances 
■ Elimination dysfunction 





■ Cognitive  
 
Diagnosis of MS 
■ Basic principles  
– Demographic profile 
• Female, Caucasian, young adult 
 
– Clinical presentation 
• Symptomatic disease, Abnormal exam 
• Flare or attack = 24 hours – up to 3 or more weeks   
 
– Laboratory profile 
• MRI 
• CSF 
• Evoked potentials 
• Exclusion of other diagnoses 
MS - Clinical Presentation 
■ Sensory tracts  
– 21%–55% of patients 
– Most common presenting symptom 
• Tingling, burning, “Novocaine-like,” band-like, squeezing 
• Lhermitte’s 
• Neuritic pain  
• Exam - Diminished vibratory sensation 
• Exam - Impaired position sense 
• “Useless hand” syndrome 
– Sensory loss, loss of position sense 
– Mobility preserved 
MS - Clinical Presentation 
■ Corticospinal tracts  
– 32%–41% of patients 
• Heaviness, weakness 
• Abnormal DTRs 
• Positive Babinski response 
• Spastic limb weakness 
MS - Clinical Presentation 
■ Brainstem 
– Eye movement abnormalities 
• Diplopia at onset in about 7% of patients 
• Nystagmus, INO 




• Peripheral 7th 
• Hearing loss and tinnitus 
MS - Clinical Presentation 
■ Visual pathway 
– Optic neuritis  
• Presenting symptom in up to 25%  
of patients 
– Dimming or visual loss 
– Loss of color vision 
– Visual field defect 
 
■ Cerebellar  
– Gait ataxia, limb ataxia, tremor 
MS - Clinical Presentation 
■ Fatigue 
– Present in up to 90% of patients with long-term MS 
– Can be seen with any Flare/Attack 
 
■ “Elimination” brainstem/spinal cord 
– Occasionally present at onset of disease 
– Bladder urgency, frequency, hesitation, nocturia 
– Bowel constipation, infrequently involuntary bowel 
movements 
MS Diagnosis 
■ Posner Criteria (1983) 
– Two clinical attacks in Space and Time 
– No other explanation 
– Paraclinical Evidence (VEP and CSF) 
• MRI not available 
 
■ McDonald Criteria  2001 
■ McDonald Criteria revised in 2005 
■ McDonald Criteria revised in 2010 
 
McDonald WI et al. Ann Neurol. 2001;50:121-127. 
McDonald Diagnostic Criteria 
■ Preserve traditional diagnostic criteria of  
2 attacks of disease separated in space  
and time 
– Must be no better explanation 
– Add specific MRI criteria, CSF findings, and analysis of evoked 
potentials as means of identifying the second “attack” 
 
■ Conclude that the outcome of the diagnostic workup should yield 1 of 
3 outcomes: 
– MS  
– Possible MS  
– Not MS 
 
McDonald MRI Criteria - 2005 
■ Abnormal MRI consistent with MS defined 
as: 
– Must have at least 3 of the following: 
• 1 gadolinium-enhancing lesion or  
9 hyperintense lesions if no  
gadolinium-enhancing lesion  
• 1 or more infratentorial lesions 
• 1 or more juxtacortical lesions 
• 3 or more periventricular lesions  
– 1 cord lesion = 1 brain lesion 
Gd-enhancing T2 hyperintense 
Juxtacortical Periventricular Spinal Cord 
Infratentorial 
McDonald MRI Criteria 
2010 Revised McDonald MRI Criteria 
■ Abnormal MRI consistent with MS defined as: 
– Dissemination in Space 
• >= 1 lesion at least 2 of the 4 characteristic areas: 
Periventricular, juxtacortical, infratentorial, spinal cord 
 
– Dissemination in Time 
• Enhancing and Non-Enhancing lesions 
• New Lesion 
• New Clinical Attack 
 
** LP and other Ancillary tests not required if no other 
explanation and above clearly seen 
** Can make diagnosis with single attack/first MRI 
Gd-enhancing T2 hyperintense 
Juxtacortical Periventricular Spinal Cord 
Infratentorial 
McDonald MRI Criteria 
Other Paraclinical Evidence 
■ Abnormal CSF 
– Oligoclonal IgG bands in CSF and not in 
serum 
– Or elevated IgG index 
 
■ Abnormal evoked potentials (VER, 
SSEP) 
– Delayed but well-preserved waveform 
Differential Diagnosis 
■ Infection 








– B12 deficiency, rare 
familial diseases 
■ CNS lymphoma 
■ Degenerative spinal 
disease 
■ Motor neuron disease 
Serum Testing 
■ B12, folate 
■ RPR, FTA 
■ HIV 
■ HTLV-1 
■ ANA, SS-A, SS-B 
■ Antiphospholipid antibodies 
■ ESR, C-reactive protein 
■ Thyroid function 
■ Angiotension-converting 
enzyme 
■ Anti-acetylcholine receptor 
antibodies 
■ Long-chain fatty acids 
 
MRI in MS 
■ MRI Brain 
– Classic Lesions =  90%–95% 
sensitivity/specificity 
– Newer data on Grey Matter Lesions 
– Brain Atrophy  
 
■ MRI Spinal Cord 
– Lesions seen in 50%–75% of cases 
• <= 1-2 vertebral levels 




■ “Black holes” 
– Thought to be areas of axonal loss 
– Can be “black holes” that are temporary with a new lesion 
 
■ Black holes not associated with a new lesion are thought 
to be areas of permanent damage 
T1 Black Holes 
Conventional T2 FLAIR 
T2-Weighted Images 
FLAIR Image 
FLAIR Image and T1 Black 
Holes 
Spinal MRI in MS 
■ Spinal cord lesions in 75% of MS patients 
■ Predominantly in C-spine 
■ Usually dorsolateral or central and 0.5 cm  
by 1–2 cm, and 1–2 vertebral segments 
■ Less likely to enhance or cause cord swelling 
■ More likely to cause progressive disease 




RRMS (2 years) 
43-year-old woman 




z score = 0 
BPF 0.85 
z score = –2.6 
BPF 0.71 
z score = –20.8 
Examples of BPF in MS 
Reprinted with permission from Rudick RA et al. Neurology. 1999;53:1698-1704. 
MS Diagnosis 
■ Two “other” Categories 
 
– Clinically Isolated Syndrome 
• First Clinical Attack 
• MRI with 1 or 2 lesions 
 
– Radiological Isolated Syndrome 
• MRI with “Classic” MS lesions 
• No clinical history 
** VEP, Cervical Spine, +/- LP 
Radiological Evidence 
Development of CDMS, stratified for baseline MRI findings. 
Modified from Miller et al.  
Study Normal MRI Abnormal MRI 
Brex et al. 19% 88% 
Optic Neuritis Study Group  
(final follow-up–15 y)3 25% 72% 
Minneboo et al. 24% 72% 
Tintore et al. 8% 63% 
38 
■ Natural history studies demonstrate that up to 88% of patients with  
1 attack and MRI lesions go on to convert to CDMS.1,2 
 
CDMS = clinically definite multiple sclerosis. 
Relationship Between No. of T2 Lesions at Baseline  
and Clinical Outcome by 20 Years in CIS Patients 
39 
Baseline Lesions 
0           
(n = 34) 
1-3             
(n = 22) 
4-9                
(n = 20) 
10+                 
(n = 31) 
CDMS at 20 yrs 7 (21%) 18 (82%) 17 (85%) 25 (81%) 
EDSS >3 at 20 yrs 9 (26%) 8 (36%) 10 (50%) 20 (65%) 
EDSS ≥6 at 20 yrs 2 (6%) 4 (18%) 7 (35%) 14 (45%) 
Fisniku LK, et al. Brain. 2008;131:808-817. 
20-Year Follow-Up of Prospectively Recruited CIS Cohort 
40 
Proposed Algorithm for Evaluating Treatment Response 
in RRMS 
Rio J, et al. Nat Rev Neurol. 2009;5:553-560. 
MS Treatment - Injectables 
■ Interferons  
– BetaSeron (QOD,SQ)  Rebif (TIW, SQ) 
– Avonex (Weekly, IM)  Extavia (QOD,SQ) 
 
– Side Affects 
• Flu like symptoms, Fatigue, Headache, Injection Problems 
 
■ Treatment tricks 
– Pre-medicate with Tylenol or Advil  
– Take medication before bed. Can disrupt sleep, so may need morning dosing 
– Determine hours until “worse” flu like symptoms and adjust shot to have them 
occur when sleeping 
 
■ Labs 
– LFTs Q6 months; TSH - yearly 
 
 
MS Treatment - Injectable 
■ Copaxone (CoPolymer) 
– Believed to be equal to Interferons when used early (CIS) 
– Presently given daily - SQ 
– Probable change to every other day (double dose 
amount) in 2013 
 
– Side Affects 
• Injection site reaction of itching at site 
• Chest Pain (rare) 
  
MS Treatment - Infusion 
■ Tysabri 
– Used for failing 1st line 
– Aggressive 1st line  
– Progression while on 1st line 
 
– Connected to PML 
• 24 months use  
• Prior Chemotherapy  
• JC virus + 
 
– Can have steroids 2 weeks before infusions for flares 
– Continued reports of improving fatigue, cognitive and strength with 
starting 





• Check monthly labs, urine at time of infusion 
• Check JC Virus before starting and every 3 months after 
– Available through Quest Labs 
• Check MRI every 6 months JC(+) or yearly JC(-) 
Requirements for PML Development:  
JCV Mutation 
■ Wild-type / benign JCV 
– Transmittable form 
– Commonly found 
in the kidney of  
healthy patients 
– May replicate 
periodically 
■ Pathogenic JCV 
– Active variant found 
in brains of PML 
patients 
– Contains mutations 
believed to increase 
viral replication and 
pathogenicity 
– Causes destruction 
of myelin-producing 
cells of the brain 
Viral 
mutations 
Evidence from multiple patient populations supports the theory that  
specific JCV mutations contribute to the development of PML 
Evaluation of JCV DNA Testing 
Quantitative PCR testing for JCV DNA   
■ 1,400 MS patients checked  (13,000 samples) 
– Blood Tests  
• <1% and not associated with the development of PML 
– Urine samples  
• 25% Positive (Prior studies = 55% ) 
 
1 / 3 patients who developed PML were urinary JCV DNA negative 
at all time points tested 
 **Results suggested JCV DNA detection in blood or urine is not 
reliable for assessment of PML risk 
Indirect Testing 
■ Check Anti-JCV Antibodies (serum) 
– Initial exposure to the virus results in formation 
of anti-JCV antibodies 
■ Once seropositive, antibodies generally 
persist even during viral latency 
■ Currently the test is available through Quest 
Labs 
Anti-JCV Antibody vs. JCV DNA 
Testing 
STRATIFY JCV Test JCV DNA Test 
Uses • Detects past JCV exposure  
(does not diagnose PML) 
• Can be used for assessment of PML risk 
• Diagnostic (CSF) for PML 
• Denotes JCV actively replicating in the 
brain 
Test type • ELISA • PCR 
Sample • Blood • Blood, urine, CSF 
Detects • Antibodies to JCV • Presence of viral components (DNA) 
Results 
indicate: 
• Any past exposure to JCV • JCV exposure, but only when JCV is 
actively replicating and shedding into 
test sample 
Ongoing Research Evaluation 
■ Among >800 MS patients tested:  
– 46% were anti-JCV antibody negative 
– 54% were anti-JCV antibody positive 
 
■ A prospective clinical trial of >30,000 MS patients is ongoing to 
evaluate STRATIFY JCV to: 
– Assess the prevalence of JCV in MS patients 
– Determine changes in JCV antibody status over time 
– Identify the correlation between JCV positivity and PML development 
 
MS Oral Treatments 
 
■ Gilenya – Fingolimod 
 
■ Initially investigated to prevent renal allograft rejection 
■ Chemically modified derivative of a fungal metabolite 
 
■ Studied against current Interferon (injectable) with:  
– 45 % reduction in relapse rate compared to Interferon.  
MS Oral Treatments 
 
■ Gilenya - Fingolimod 
– Mechanism of Action 
• Agonist to S1P receptors 
– When Phosphorylated 
 
• Gilenya  acts to sequester circulating lymphocytes into secondary 
lymphoid organs 
 
• No effect on lymphocyte induction, proliferation, or memory function 
 
• Lymphocyte counts decreased by 72-77%   
 
• Peripheral reduction of  
– CD3+, CD4+, CD8+,     - CD45RO+ (memory T cells),  
– CD45RA+ (naive T cells),    - CD19+ cells   
Gilenya - Cardiac 
Number (%) of 
Participants 







Bradycardia 0 2 (0.5%) 10 (2.4%) 
Second Degree AV   Block 0  1 (0.2%) 3 (0.7%) 
Firist Degree AV Block 0 1 (0.2%) 2 (0.5%) 
Infections 
Appendicitis 2 (0.5%) 0 2 (0.5%) 
Herpes viral infections 1 (0.2%) 1 (0.2%) 3 (0.7%) 
Dyspnea 0 0 2 (0.5%) 
* Cardiac Complications with First dose believed due to internalization of SP receptors 
MS Oral Therapies  
Gilenya (Fingolimod) 
■ FDA Requirements 
■ A. 6 hour Observation with EKG 
with first dose and prior to 
leaving 
– Blood pressure every 
hour 
■ B.  OCT exam before and at 3-4 
months 
■ C. Varicella Titer 
 
■ MS Center of Lehigh Valley 
Gilenya Protocol 
– A. 6 hour Telemetry 
Monitoring 
*Dr. Spikol 
– B. OCT exam before and 
at 3-4 months   
– C. Varicella Titer   
– D. Cancer Screening   
• Dermatology  
• Male/Female 
Standard Guidelines 
– Breast, Pelvic, 
Testicular, Colon 
 
MS Oral Therapies – Aubagio 
(Teriflunomide) 
■ Aubagio 
– FDA approved October 2012 
– Active component of Leflunomide 
 
■ Major Side Effects 
– Liver Affect 
– Alopecia 
– Birth Defects 
MS Oral Therapies - Teriflunomide 
■ Teriflunomide is the active metabolite of leflunomide 
– Leflunomide is FDA-approved in adults for the treatment of active rheumatoid arthritis  
  
 
■ Teriflunomide is being developed for the treatment of multiple sclerosis:  
– Eliminates other metabolites of leflunomide 
• Although it is a minor pathway, these metabolites may themselves have adverse effects 
– Avoids the hepatic metabolism of leflunomide to teriflunomide 
– Reduces CYP450 involvement compared with leflunomide, which may decrease 
potentially  clinically significant drug–drug interactions 
Leflunomide Teriflunomide 
(A77 1726, HMR1726) 
TERIFLUNOMIDE 
Dihydroorotate Dehydrogenase (DHODH) 
Teriflunomide: Proposed MOA in MS 
Teriflunomide selectively and reversibly inhibits DHODH  
– a key mitochondrial enzyme in de novo pyrimidine synthesis required by 
rapidly dividing lymphocytes  
– Cystostatic   
– Limit over-activation of the activated and autoimmune Lymphocytes 
– Protective immunity is not significantly affected by Teriflunomide 
A77 1726 
§ 
MS Oral Therapies - 
Teriflunomide 
■ Leflunomide Experience 
– Cases of Lymphoma have been seen 
• However increase in case with all RA treatments 
(MethoTrexate, Cyclosporin) 
– Severe Liver Necrosis with fatalities have 
occurred 
• Seen within first 6 months of therapy 
– Severe Infections have been seen 
• TB, Pneumonia, PCP, Mycotic 
 
Teriflunomide 
■ TEMSO (Teriflunomide Multiple Sclerosis 
Oral trial) 
– Decrease in Annual Relapse Rate (vs Placebo) 
• 7 mg dose – 31.2 % 
• 14 mg dose – 31.5 % 
■ TOWER 
– Decrease in Annual Relapse Rate (vs Placebo) 
• 7 mg – 22.3 % 
• 14 mg – 36.3 % 
MS Oral Therapies - DMF   
 
■ DMF (dimethyl fumarate)  
– Derived from Fumaderm, an oral therapy of fumaric acid  
esters  
– Approved to treat psoriasis in Germany 
 
■ Initial Proposed FDA approval – December 2013 
 
■ Proposed for Mid 2013 
– FDA needed extended time to review Data. 
– Did not require more / additional data 
MS Oral Therapies - DMF   
■ DMF (DiMethyl Fumarate) 
– Therapeutic mechanism in MS is speculative 
• Psoriasis Data -  
– Beneficial effect coincides with Lymphocytopenia  
» Decreased by 40%-60%  
– Down-regulation of proinflammatory cytokines 
– Increase in Antiinflammatory cytokine IL-10  
– Upregulation of Nuclear Factor 2 
– Induces Anti-Inflammatory Stress Protein HO-1 
 
• Protective antioxidant pathway in CNS 
– Unpublished data in the EAE model   
 
MS Oral Therapies - DMF   
■ DEFINE:   
– Placebo-controlled, 1011 patients 
• Low-dose : 240 mg BID 
• High-dose : 240 mg TID 
• Annualized relapse rate 
– Results 
• Two year ARR –  
– Placebo = 36%, BID = 17%, TID = 19% 
 
 
■ CONFIRM:   
– High- and low-dose vs Copaxone®   
– Subjects (N~1232): RRMS by MacDonald, EDSS <5 
– Primary outcome: Annualized relapse rate 
– Results  
• Two year ARR –  




■ MRI is now major diagnostic tool 
– Can diagnose with first attack / MRI 
– Clinically Isolated Syndrome and 
Radiological Isolated Syndrome 
categories 
■ New Oral Therapies  
